Abstract: Therapeutics and methods of treating COVID-19 comprising in a patient comprising administering to the patient an effective dose of a pharmacologic composition containing a first therapeutic; wherein the first therapeutic is a hydrogen sulfide (H2S) donor, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment the H2S donor is one of include diallyl trisulfide (DATS), diallyl disulfide (DADS), sodium sulfide, acillin, sugammadex, sulfanilamide, disulfram, sulfonamide, a sulfinate, a sulfoxide, a persulfide, a polysulfide, and a sulfone. According to a further embodiment the pharmacologic composition further contains a second therapeutic, wherein the second therapeutic is a nitrite, or a salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analogs thereof. According to a further embodiment wherein the nitrite is an inorganic nitrite.

Abstract: A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.

Abstract: A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.